A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects
Latest Information Update: 16 Jan 2020
At a glance
- Drugs Tenofovir exalidex (Primary) ; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors ContraVir Pharmaceuticals; Hepion Pharmaceuticals
- 24 Oct 2017 Results of phase IIa portion of this study presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 12 Sep 2017 Status changed from recruiting to completed.
- 08 Aug 2017 According to a ContraVir Pharmaceuticals media release, data from the study will be presented at the American Association for the Study of Liver Diseases (AASLD).